| Dr David John Homan, MD | |
|
1233 Wayne Gilmore Cir, Suite 450, Opelousas, LA 70570-6405 | |
| (337) 942-3006 | |
| (337) 942-7744 |
| Full Name | Dr David John Homan |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 18 Years |
| Location | 1233 Wayne Gilmore Cir, Opelousas, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164681334 | NPI | - | NPPES |
| 1941786 | Medicaid | LA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Opelousas General Health System | Opelousas, LA | Hospital |
| Mercy Regional Medical Center | Ville platte, LA | Hospital |
| Acadia St Landry | Church point, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Opelousas General Hospital Authority | 1456332865 | 7 |
| Cardiovascular Institute Of The South, Llc | 3779497441 | 129 |
News Archive
One in 330 children will be diagnosed with some form of cancer by the time they are 20-years-old. Because treatment plans differ for each of the many forms of the disease, families often have to travel to seek the best care for their child.
Using state of the art imaging technology a team from Yale School of Medicine has glimpsed one of the cell's most important 'nano-machines' in action. The work, performed in collaboration with English and French scientists, provides new insight into the machinery cells use to internalize cell surface receptors.
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Many states do not have the policy or environmental measures in place to help their residents meet the recommended levels of physical activity to promote health, according to a report released today by the Centers for Disease Control and Prevention.
› Verified 2 days ago
| Entity Name | Cardiovascular Institute Of The South, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982689113 PECOS PAC ID: 3779497441 Enrollment ID: O20031117000706 |
News Archive
One in 330 children will be diagnosed with some form of cancer by the time they are 20-years-old. Because treatment plans differ for each of the many forms of the disease, families often have to travel to seek the best care for their child.
Using state of the art imaging technology a team from Yale School of Medicine has glimpsed one of the cell's most important 'nano-machines' in action. The work, performed in collaboration with English and French scientists, provides new insight into the machinery cells use to internalize cell surface receptors.
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Many states do not have the policy or environmental measures in place to help their residents meet the recommended levels of physical activity to promote health, according to a report released today by the Centers for Disease Control and Prevention.
› Verified 2 days ago
| Entity Name | St Francis Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437149168 PECOS PAC ID: 7810892718 Enrollment ID: O20031204000183 |
News Archive
One in 330 children will be diagnosed with some form of cancer by the time they are 20-years-old. Because treatment plans differ for each of the many forms of the disease, families often have to travel to seek the best care for their child.
Using state of the art imaging technology a team from Yale School of Medicine has glimpsed one of the cell's most important 'nano-machines' in action. The work, performed in collaboration with English and French scientists, provides new insight into the machinery cells use to internalize cell surface receptors.
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Many states do not have the policy or environmental measures in place to help their residents meet the recommended levels of physical activity to promote health, according to a report released today by the Centers for Disease Control and Prevention.
› Verified 2 days ago
| Entity Name | Opelousas General Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750507281 PECOS PAC ID: 1456332865 Enrollment ID: O20040601000024 |
News Archive
One in 330 children will be diagnosed with some form of cancer by the time they are 20-years-old. Because treatment plans differ for each of the many forms of the disease, families often have to travel to seek the best care for their child.
Using state of the art imaging technology a team from Yale School of Medicine has glimpsed one of the cell's most important 'nano-machines' in action. The work, performed in collaboration with English and French scientists, provides new insight into the machinery cells use to internalize cell surface receptors.
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Many states do not have the policy or environmental measures in place to help their residents meet the recommended levels of physical activity to promote health, according to a report released today by the Centers for Disease Control and Prevention.
› Verified 2 days ago
| Entity Name | Lafayette Health Ventures Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417986092 PECOS PAC ID: 9335043074 Enrollment ID: O20041105000263 |
News Archive
One in 330 children will be diagnosed with some form of cancer by the time they are 20-years-old. Because treatment plans differ for each of the many forms of the disease, families often have to travel to seek the best care for their child.
Using state of the art imaging technology a team from Yale School of Medicine has glimpsed one of the cell's most important 'nano-machines' in action. The work, performed in collaboration with English and French scientists, provides new insight into the machinery cells use to internalize cell surface receptors.
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Many states do not have the policy or environmental measures in place to help their residents meet the recommended levels of physical activity to promote health, according to a report released today by the Centers for Disease Control and Prevention.
› Verified 2 days ago
| Entity Name | Lsuhn Billing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992975775 PECOS PAC ID: 0446337802 Enrollment ID: O20080409000372 |
News Archive
One in 330 children will be diagnosed with some form of cancer by the time they are 20-years-old. Because treatment plans differ for each of the many forms of the disease, families often have to travel to seek the best care for their child.
Using state of the art imaging technology a team from Yale School of Medicine has glimpsed one of the cell's most important 'nano-machines' in action. The work, performed in collaboration with English and French scientists, provides new insight into the machinery cells use to internalize cell surface receptors.
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Many states do not have the policy or environmental measures in place to help their residents meet the recommended levels of physical activity to promote health, according to a report released today by the Centers for Disease Control and Prevention.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David John Homan, MD Po Box 4176, Houma, LA 70361-4176 Ph: (985) 876-0300 | Dr David John Homan, MD 1233 Wayne Gilmore Cir, Suite 450, Opelousas, LA 70570-6405 Ph: (337) 942-3006 |
News Archive
One in 330 children will be diagnosed with some form of cancer by the time they are 20-years-old. Because treatment plans differ for each of the many forms of the disease, families often have to travel to seek the best care for their child.
Using state of the art imaging technology a team from Yale School of Medicine has glimpsed one of the cell's most important 'nano-machines' in action. The work, performed in collaboration with English and French scientists, provides new insight into the machinery cells use to internalize cell surface receptors.
Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).
Many states do not have the policy or environmental measures in place to help their residents meet the recommended levels of physical activity to promote health, according to a report released today by the Centers for Disease Control and Prevention.
› Verified 2 days ago
Fernando Alemany, M.D., Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3975 I-49 S Services Rd, Suite 200, Opelousas, LA 70570 Phone: 337-594-0750 Fax: 337-594-0752 | |
Anthony Paul Blalock, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1270 Attakapas Dr, Suite 103, Opelousas, LA 70570 Phone: 337-407-1777 Fax: 337-407-1199 | |
Dr. Gary Wayne Blanchard, Internal Medicine Medicare: Medicare Enrolled Practice Location: 1270 Attakapas Dr, Ste 502, Opelousas, LA 70570 Phone: 337-942-9977 Fax: 337-942-8006 | |
Dr. Usman Alam, M.D., Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 611 E Prudhomme St, Suite 3, Opelousas, LA 70570 Phone: 337-942-5750 Fax: 337-948-9405 | |
Dr. Richard Tate, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 138 Lazaro Blvd, Suite A, Opelousas, LA 70570 Phone: 337-942-2065 Fax: 337-942-9964 | |
Dr. Louis Howard Nix, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 Hospital Dr, Suite 4, Opelousas, LA 70570 Phone: 337-948-7090 Fax: 337-942-8108 |